RC
RCUS
Market ClosedArcus Biosciences, Inc.
US
601 employees
CEO: Terry J. Rosen
Founded: 2018
$22.86
+$0.00(+NaN%)
Market Cap
2.88B
Beta
0.81
52W Range
N/A
Dividend Yield
0.00%
Forecasting Analysis
AI-powered predictions and statistical risk modeling for short-term price movements
AI Insight:
Arcus Biosciences exhibits marginal downside risk in the short term with AI forecasts trending lower. Analyst consensus displays strong coverage but wide disagreement, indicating varied expectations over the next year. This divergence suggests potential volatility and differing views on future performance.
Current Price
N/A
Last closing price
Price Prediction
Machine learning prediction based on historical price patterns
Period:
Analyst Price Target for RCUS
Loading analyst price targets...
Wall Street Forecasts
Revenue Forecast
Past Growth
N/A
Based on Historical CAGR
Forward Growth
N/A
Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
Revenue Analysis
Comparison of Actual and Estimated Revenues
Loading chart data...
Revenue growth steady at 0.0%.
Operating Profitability Forecast
Past Growth
N/A
EBITDA Historical CAGR
Forward Growth
N/A
EBITDA Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
EBITDA Analysis
Comparison of Actual and Estimated EBITDA
Loading chart data...
EBITDA maintaining 0.0% trajectory.
Earnings Per Share Forecast
Past Growth
N/A
EPS Historical CAGR
Forward Growth
N/A
EPS Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
EPS Analysis
Comparison of Actual and Estimated Earnings Per Share
Loading chart data...
EPS growth stable around 0.0%.
Explore RCUS
RCUS in the Healthcare
Mid Cap